Embardia 40mcg/0.4ml Injection 1pc

Composition of Embardia 40mcg/0.4ml Injection

DARBEPOETIN ALFA 

Uses of Embardia 40mcg/0.4ml Injection

Treatment of Anaemia (in cancer and chronic kidney disease)

Side Effects of Embardia 40mcg/0.4ml Injection

• Hypertension
• Stroke
• Thromboembolic events
• Seizures
• Allergic reactions
• Pure Red Cell Aplasia (PRCA)

Quick Suggestions:

Indication of Embardia 40mcg/0.4ml Injection

Embardia (Darbepoetin alfa) is indicated for the treatment of anemia due to:

• Chronic Kidney Disease (CKD) in patients on dialysis and those not on dialysis.
• Anemia in patients receiving myelosuppressive chemotherapy, with at least two additional months of planned chemotherapy upon treatment initiation.

Pharmacology

Darbepoetin alfa is an erythropoiesis-stimulating agent (ESA). It is produced through recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. It stimulates the production of red blood cells by acting on erythroid progenitor cells, similar to erythropoietin. Darbepoetin alfa differs from recombinant human erythropoietin by having five N-linked oligosaccharide chains (compared to three), leading to an extended half-life and prolonged activity.

Dosage & Administration of Embardia 40mcg/0.4ml Injection

Chronic Renal Failure (Adult Patients):

• Correction phase: Initial dose of 0.45 µg/kg once weekly via subcutaneous or intravenous route. For patients not on dialysis, 0.75 µg/kg can be given every two weeks or 1.5 µg/kg once monthly.
• Maintenance phase: This can be administered weekly, biweekly, or once monthly depending on the patient's hemoglobin level and dialysis status.

Chronic Renal Failure (Pediatric Patients ≥1 year):

• Correction phase: 0.45 µg/kg once weekly subcutaneously or intravenously, or 0.75 µg/kg every two weeks for non-dialysis patients.
• Maintenance phase: Same as adults, with possible higher doses for children under 6 years.

Chemotherapy-Induced Anemia (Adult Cancer Patients):

• Initial dose: 500 µg once every three weeks, or 2.25 µg/kg once weekly.

Administration Guidelines:

• Do not shake or freeze.
• Protect from light and inspect for particulates or discoloration before use.
• Do not dilute or mix with other drug solutions.

Drug Interactions:

• No formal drug interaction studies have been conducted with Darbepoetin alfa.

Contraindications

• Uncontrolled hypertension
• Pure Red Cell Aplasia (PRCA)
• History of serious allergic reactions to Darbepoetin alfa

Overdose Management:

• Overdose may result in elevated hemoglobin levels, which can be managed by stopping or reducing the dose and/or phlebotomy.

Pregnancy & Lactation

• Pregnancy Category C: Not enough data is available to determine potential harm to a fetus.
• It is not known whether Darbepoetin alfa is excreted in breast milk; use with caution in nursing mothers.

Precautions & Warnings

• Use with caution in patients with controlled hypertension, seizures, or a history of PRCA or allergies to Darbepoetin alfa.
• Monitor hemoglobin levels closely to avoid exceeding recommended levels.

Storage:

• Store at 2°C to 8°C.
• Do not freeze or shake.
• Protect from light, and store in the carton until use.